Dollar General (DG) Lined Up for Q4 Earnings: Factors to Note
https://www.zacks.com/stock/news/2239956/dollar-general-dg-lined-up-for-q4-earnings-factors-to-note?cid=CS-ZC-FT-analyst_blog|earnings_preview-2239956
Mar 13, 2024 - While Dollar General (DG) navigates softening sales trends, it is focusing on enhancing the supply chain, offering customer-friendly prices and embracing digitization.
0
FTI Consulting (FCN) Benefits Globally Despite High Costs
https://www.zacks.com/stock/news/2241497/fti-consulting-fcn-benefits-globally-despite-high-costs?cid=CS-ZC-FT-analyst_blog|zer_report_update-2241497
Mar 15, 2024 - FTI Consulting (FCN) gains from diversification, global expansion and share buybacks amid rising investment costs and low liquidity.
0
Southern Copper (SCCO) Bets on Strong Projects Amid Cost Woes
https://www.zacks.com/stock/news/2242399/southern-copper-scco-bets-on-strong-projects-amid-cost-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2242399
Mar 18, 2024 - Southern Copper (SCCO) is poised to grow on the back of its copper reserves and solid growth projects. However, inflationary pressures will impact margins in the near term.
0
East West Bancorp (EWBC) Rides on High Rates Amid Rising Costs
https://www.zacks.com/stock/news/2242982/east-west-bancorp-ewbc-rides-on-high-rates-amid-rising-costs?cid=CS-ZC-FT-analyst_blog|zer_report_update-2242982
Mar 19, 2024 - East West Bancorp (EWBC) remains well-poised for growth amid decent loan demand, high rates and continued client acquisition efforts. However, elevated expenses and poor asset quality are worrisome.
0
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035
Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
0
Regions Financial (RF) Rides on Loan Growth, High Costs Ail
https://www.zacks.com/stock/news/2242846/regions-financial-rf-rides-on-loan-growth-high-costs-ail?cid=CS-ZC-FT-analyst_blog|zer_report_update-2242846
Mar 19, 2024 - Regions Financial (RF) benefits from consistent growth in loan balances and strategic buyouts. However, rising expenses and lack of loan portfolio diversification are major headwinds.
0
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405
Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
0
Voya Financial (VOYA) Banks on Segmental Growth Amid Cost Woes
https://www.zacks.com/stock/news/2245347/voya-financial-voya-banks-on-segmental-growth-amid-cost-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2245347
Mar 25, 2024 - Voya Financial (VOYA) stands to gain from strategic acquisitions, favorable retention, improved investment income and stronger surplus income.
0
Inter Parfums (IPAR) Benefits From Solid Demand Amid Cost Woes
https://www.zacks.com/stock/news/2246729/inter-parfums-ipar-benefits-from-solid-demand-amid-cost-woes?cid=CS-ZC-FT-analyst_blog|rank_focused-2246729
Mar 27, 2024 - Continuous innovation in developing and marketing its range of fragrances, combined with the strength of the fragrance market, positions Inter Parfums (IPAR) well.
0
BlackRock's (BLK) Restructuring Efforts Aid Amid Cost Woes
https://www.zacks.com/stock/news/2247454/blackrock-s-blk-restructuring-efforts-aid-amid-cost-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2247454
Mar 28, 2024 - BlackRock (BLK) remains well-positioned for top-line growth, supported by its restructuring initiatives and expansion efforts. Yet, elevated expenses and geopolitical risks are concerns.
0